Avid Bioservices, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024
For the nine months, sales was USD 96.94 million compared to USD 109.47 million a year ago. Net loss was USD 17.65 million compared to net income of USD 0.594 million a year ago. Basic loss per share from continuing operations was USD 0.28 compared to basic earnings per share from continuing operations of USD 0.01 a year ago. Diluted loss per share from continuing operations was USD 0.28 compared to diluted earnings per share from continuing operations of USD 0.01 a year ago.